

Sensorineural Hearing Loss in Newborns Hospitalized in Neonatal Intensive Care Unit: An Observational Study

Arianna Di Stadio¹
Egisto Molini¹
Valeria Gambacorta¹
Giorgia Giommetti¹
Antonio della Volpe²
Massimo Ralli³ *
Ruggero Lapenna⁴
Franco Trabalzini⁴
Giampietro Ricci¹

Abstract

Children hospitalized in Neonatal Intensive Care Units (NICU) present an increased risk for Sensorineural Hearing Loss (SNHL) due to prematurity, hypoxia-ischemia, hyperventilation, low birth weight and the use of ototoxic drugs. The aim of this study was to assess the prevalence of SNHL in newborns hospitalized in a NICU using Transient Evoked Otoacoustic Emissions (TEOAE) and Automated Auditory Brainstem Responses (A-ABR) and analyze the associated risk factors. A sample of 153 newborns hospitalized in NICU underwent TEOAE, A-ABR and clinical ABR to evaluate the presence of hearing deficits. Prevalence of SNHL was calculated and odds ratio for specific risk factors was measured. One-hundred fifteen babies (86.7%) presented normal hearing at TEOAE and A-ABR. Fifteen children had a REFER response at TEOAE and a PASS response at A-ABR. Twenty-five children (16.3%) had a REFER A-ABR and were addressed to clinical ABR. A diagnosis of SNHL was made in 12 (7.8%) newborns. An increased risk of SNHL was observed in preterm children <28 weeks ($p=0.0135$), in children with neurological disorders ($p=0.02$), that underwent surgery ($p=0.0002$), affected from premature retinopathy ($p=0.0006$), craniofacial malformation ($p=0.007$) and that had sepsis ($p=0.04$). Additional risk factors for SNHL in our sample were a maternal disease during pregnancy ($p=0.0011$), cesarean delivery ($p<0.0001$) and a twin pregnancy ($p<0.0001$). SNHL in newborns is correlated with hospitalization in NICU. An accurate hearing screening associated to a rigorous clinical medical collection of data is necessary to promptly identify cases of SNHL in children with a special attention to those hospitalized in NICU and plan proper intervention.

Keywords: Congenital hearing loss; risk factors; newborn universal hearing screening; neonatal intensive care unit.

¹Department of Surgical and biomedical sciences, University of Perugia, Italy

²Department of Cochlear Implant unit, Naples Italy

³Department of Sense organs, Sapienza University of Rome, Italy

⁴Department of Otolaryngology, Meyer Children University hospital, Florence, Italy

*Send correspondence to:

Massimo Ralli

Department of Sense Organs, Sapienza University of Rome, Italy. E-mail: massimo.ralli@uniroma1.it; Phone: +00390649976808

Paper submitted to the ITJ-EM (Editorial Manager System) on March 27, 2019; and accepted on May 08, 2019.

INTRODUCTION

Sensorineural Hearing Loss (SNHL) in newborns represents a common condition with serious effects on the ability to develop speech, language and social skills¹⁻³. The prevalence of SNHL ranges from 1 to 3 per thousand newborns⁴⁻¹³. Universal newborn hearing screening programs are available in most industrialized countries and help early identification, diagnosis and intervention in infants with hearing loss⁴⁻¹¹. Admission to a Neonatal Intensive Care Units (NICU) is considered a risk factor for SNHL, as documented by the Joint Committee on Infant Hearing (JCIH)¹⁴, due to many conditions including prematurity, hypoxia-ischemia, hyperventilation, low birth weight and the use of ototoxic drugs¹⁵⁻²². Prevalence of SNHL in children admitted in NICU is nearly 4%^{23,24}. The aim of this study was to assess the prevalence of SNHL in new born admitted to a NICU using Transient Evoked Otoacoustic Emissions (TEOAE) and Automated Auditory Brainstem Responses (A-ABR) and analyses the associated risk factors.

MATERIALS AND METHODS

This prospective study was conducted in a University hospital between March and November 2017. All newborns admitted to the NICU of our hospital were included in the study. The study was approved by the institutional review board of the hospital without release of a referee number. The study was performed in accordance with the Declaration of Helsinki for human rights. All parents of the newborns included in the study signed a written consent authorizing the inclusion.

Collection of data from medical records and clinical observation

The following data were collected for each subject: sex, age (in months), prematurity, family history for genetic SNHL, presence of chromosomal disorders, consanguinity between parents, maternal infections, Apgar score at 1' < 5 or/and at 5' < 7, use of mechanical ventilation for more than 5 days, presence of meconium aspiration syndrome, neurologic disorders, cerebral complications, hyperbilirubinemia and necessity of phototherapy or exchange transfusion, low birth weight, surgery, presence of Retinopathy of Prematurity (ROP), craniofacial malformations, sepsis, use of antibiotics included the known ototoxic, maternal diseases during pregnancy, maternal use of medicines during pregnancy,

assisted conception, caesarean section, twin pregnancy (Table 1). The risks were classified by their prevalence as common when they affected >50% of the children, less common if <50%, rare if < 10% and extremely rare when the condition was present in <2% of the children.

Collection of audiological data

Two expert audiology technicians recorded TEOAE and A-ABR in all children hospitalized in the NICU of our hospital. The results of the tests were analysed by a physician with more than 20 years of experience in audiology.

TEAOE test was executed placing the earplugs in both ears, one ear at a time, during sleep or at the end of feeding. TEOAE were recorded in both ears by using Eroscaan Screener OAE Maico Diagnostic and the results were documented as either PASS or REFER. TEOAE were recorded with a non-linear click-sequence stimulus at intensity of 70 dB SPL level (45 dB HL), with a click rate of approximately 60 Hz and a frequency range between 1.4 and 4.5 kHz. A-ABR was performed using Integrity V500 equipment. The test required less than 2 minutes for its execution. Electrodes were placed on the newborn's forehead, nape and shoulder for detecting the responses from the auditory brainstem. The screening was done in a quiet room during sleep; evaluation was based on noise-weighted averaging and sample masking using a click stimulus of 40 dB nHL. The clicks were delivered by ER-3C insert earphones. The electrophysiological signals were amplified and analyzed. Children with a unilateral or bilateral REFER response in A-ABR were further investigated using clinical ABR to confirm the presence or the absence of SNHL before six months of age. ABR signals were recorded with Eclipse (Interacustics) in clinical, automatic modality using a decreasing (100 dB to 10 dB) single click stimulus. Contralateral masking was applied if asymmetric responses were observed²³⁻²⁵. After cleaning skin with abrasive paste, silver plated surface electrodes were applied in conventional positions using adhesive tape (black-left or right earlobe, red-Fz, green-breastbone). In accordance to actual ABR criteria, we analysed the absolute latency of waves I, III, and V, interpeak latencies (I-III, III-V, I-V), interaural difference of interpeak I-V. ABR was considered within normal range if a wave V could be found with at least two repetitions at 60 dB SPL (35 dB nHL) with normal latency and interpeak values for patient's age. We also investigated the presence

Table 1. Risk factors evaluated in our sample.

| | |
|-------------------------------|--|
| Maternal infections | Cytomegalovirus, Toxoplasma, Rubeola, Candida albicans, E.coli, Chlamydia, Syphilis, Mycoplasma and Hepatite C virus |
| Maternal diseases | hypothyroidism, pre-eclampsia, hypertension, gestational diabetes |
| Cerebral complications | brain hemorrhage, Germinal Matrix Hemorrhage (GMH), cerebellar hypoplasia, stroke, hydrocephalus, oloprosocephalia, cerebral hematoma and alteration of lateral ventriculi |
| Antibiotics | amphotericine, metramidazol, clarytromicine, amoxycilline, tobramicine, ampycilline, netilmicin, vancomicine, meropenem, amikacine, genatmicine, piperacilline, benzilpenicelline, teicoplanine, ceftaxidime |
| Chromosomic mutations | trisomy 13, microcephaly, polydactilia |
| Surgery | plastic, ocular, abdominal, cardiologic surgeries and tracheostomy |

of conductive hearing loss in all patients; conductive hearing loss was diagnosed with a positive otoscopy for middle ear disorders, a type B or C tympanogram with absent acoustic reflexes, and increased values of waves I, III and V absolute latency with normal I-III, III-V and I-V interpeaks.

Statistical analysis

The prevalence of hearing loss was calculated. Odds ratio

was calculated for each risk factor. P was considered as significant <0.05.

RESULTS

Hearing function

Our sample included 153 children, 84 males and 69 females, with an average gestational age of 33 weeks (23-42 weeks). One-hundred thirteen babies (73.9%) presented normal hearing at TEOAE and A-ABR. Fifteen children (9.8%) had a REFER response at TEOAE and a PASS response at A-ABR. Twenty-five children (16.3%) had a REFER A-ABR response and were addressed to clinical ABR evaluation (Figure 1). All children with altered A-ABR results underwent clinical ABR. The results of clinical ABR showed that 12/25 (48%) children had a moderate (41 to 55 dB HL) and profound (>91 dB HL) SNHL; 11/25 (44%) were false positives and had a normal hearing. Among children with hearing loss, four (33.4%) had a unilateral profound SNHL, three (25%) a bilateral profound SNHL, three (25%) a unilateral moderate SNHL, one (8.3%) a bilateral moderate SNHL and one (8.3%) received a diagnosis of auditory neuropathy (Figure 2). Two children were lost during follow up.

Risk factors

Conditions observed in our sample are detailed in Table 2. Prematurity was observed in 84.9% (130 children) of patients hospitalized in the NICU; 87 children (56.9%) stayed in NICU more than 5 days. None of the children




Figure 1. Results of Transient Evoked Otoacoustic Emissions (TEOAE) and Automated Auditory Brainstem Responses (A-ABR) tests.

Table 2. Conditions observed in our sample sorted by children with Sensorineural Hearing Loss (SNHL), false positives and children with normal hearing.

| Risk Factor | SNHL (N=12) | False Positives (N=11) | Normal Hearing(N=130) |
|--|---------------|------------------------|-----------------------|
| Prematurity | 12 (28 weeks) | 11 (31 weeks) | 107 (32 weeks) |
| Hospitalization in Neonatal Intensive Care Unit (NICU) over 5 days | 10 | 7 | 70 |
| Family anamnesis of genetic sensorineural hearing loss | 0 | 0 | 0 |
| Chromosomal disorders | 2 | 1 | 5 |
| Consanguinity | 0 | 0 | 1 |
| Maternal infections | 2 | 3 | 14 |
| Apgar score at 1' < 5 or/and at 5' < 7 | 1 | 1 | 12 |
| Mechanical ventilation for more than 5 days | 7 | 4 | 41 |
| Meconium aspiration syndrome | 0 | 0 | 0 |
| Neurologic disorders | 1 | 0 | 0 |
| Cerebral complications | 1 | 2 | 19 |
| Hyperbilirubinemia | 0 | 0 | 2 |
| Low birth weight | 12 (1015 gr) | 10 (1655 gr) | 95 (1682 gr) |
| Surgery | 6 | 0 | 0 |
| Presence of retinopathy of prematurity | 6 | 2 | 12 |
| Craniofacial malformations | 2 | 0 | 0 |
| Sepsis | 3 | 2 | 8 |
| Use of antibiotics | 10 | 6 | 82 |
| Use of ototoxic antibiotics | 10 | 6 | 79 |
| Maternal diseases during pregnancy | 4 | 3 | 3 |
| Maternal use of medicines during pregnancy | 2 | 0 | 0 |
| Assisted procreation | 1 | 1 | 1 |
| Caesarean childbirth | 8 | 6 | 6 |
| Twin pregnancy | 4 | 4 | 4 |

Degree of sensorineural hearing loss (SNHL)




Figure 2. Degree of sensorineural hearing loss (SNHL) found in our sample.

had a positive history for genetic SNHL and meconium aspiration syndrome.

In children with a clinical diagnosis of SNHL (n=12), prematurity (<28 weeks) and low weight at birth were common findings in all subjects (n=12, 100%), followed by hospitalization in NICU for more than 5 days (n=10, 83.3%), the use of ototoxic antibiotics (n=10, 83.3%), caesarian childbirth (n=8, 66.6%), mechanical ventilation over 5 days (n=7, 58.3%), retinopathy of prematurity (ROP) (n=6, 50%) and surgery (n=6, 50%). Less-common findings were twin pregnancy (n=4, 33.3%) and maternal disease during the pregnancy (n=4, 33.3%) followed by sepsis (n=3, 25%), maternal infections (n=2, 16.7%), chromosomal disorders (n=2, 16.7%), craniofacial malformations (n=2, 16.7%) and maternal use of medicines during pregnancy (n=2, 16.7%). Rare findings were low Apgar score (n=1, 8.3%), neurological disorders (n=1, 8.3%), cerebral complication (n=1, 8.3%) and assisted procreation (n=1, 8.3%). In this group, we did not observe any case of consanguinity and hyperbilirubinemia. In children with normal hearing function (n=141), prematurity (>31 weeks) was the most common finding (n=118, 83.7%) followed by low weight at birth (n=105, 74.4%), use of ototoxic antibiotics (n=85, 60.3%) and hospitalization in NICU more than 5 days (n=77, 54.6%). Less common observations were mechanical ventilation over 5 days (n=45, 31.9%), cerebral complications (n=21, 14.9%), maternal infections (n=17, 12%). Rare findings were ROP (n=14, 9.9%), low Apgar score (n=13, 9.2%), caesarean childbirth (n=12, 8.5%), sepsis (n=10, 7%), twin pregnancy (n=8, 5.6%), chromosomal disorders (n=6, 4.2%) and maternal disease during the pregnancy (n=6, 4.2%). Very rare findings included hyperbilirubinemia and necessity of phototherapy or exchange transfusion (n=2, 1.4%), assisted procreation (n=2, 1.4%) and consanguinity (n=1, 0.7%). In this group, we did not observe any case of surgery, maternal use of medicines during pregnancy, and neurological disorders (Table 3).

Odds ratio for each specific finding

We identified an increased risk of developing SNHL for

Table 3. Antibiotic treatment in children with Sensorineural Hearing Loss (SNHL) and with normal hearing.

| Antibiotic | SNHL (N=12) | Normal Hearing (n=141) |
|------------------|-------------|------------------------|
| Ampicilline | 83.30% | 73.80% |
| Netilmicine | 83.30% | 72.70% |
| Meropenem | 41.60% | 11.40% |
| Tobramicine | 25% | 10.20% |
| Claritromicine | 25% | 13.60% |
| Metromidazole | 8.30% | 2.20% |
| Anfotericine | 8.30% | 1% |
| Vancomicine | 50% | 20.40% |
| Teicoplanine | 8.30% | 2.20% |
| Amikacine | 8.30% | 3.40% |
| Gentamicine | 8.30% | 2.20% |
| Piperacilime | 0% | 0% |
| Ceftazidime | 0% | 2.20% |
| Amoxicilline | 0% | 13.60% |
| Benzipenicilline | 0% | 1.10% |

nine of the twenty risk factors included in the analysis. In particular, SNHL was statistically associated with: prematurity <28 weeks (odds ratio: 35.9677; CI 95%: 2.0981 to 616.5861; p=0.0135), neurological disorders (odds ratio: 36.9130; CI 95%: 1.4219-958.3075; p=0.02), surgery (odds ratio: 283.0000; CI 95%: 14.3455-5582.8589; p=0.0002), ROP (odds ratio: 9.0714; CI 95%: 2.5756-32.9499; p=0.0006), craniofacial malformation (odds ratio: 67.3810; CI 95%: 3.0341-1496.4081; p=0.007), sepsis (odds ratio: 4.3667; CI 95%: 1.0178-18.7336; p=0.04), maternal disease during pregnancy (odds ratio: 11.2500; CI 95%: 2.6327-48.0729; p=0.0011), caesarean childbirth (odds ratio: 21.5000; CI 95%: 5.6404-81.9536; p<0.0001) and twin pregnancy (odds ratio: 33.2500; CI 95%: 8.2297-134.3389; p<0.0001). The other eleven risk factors did not show odds ratio with a statistically significant value. The odds ratio of these risk factors were: hospitalization in NICU over 5 days (odds ratio: 4.1558; CI 95%: 0.8786-19.6584; p=0.07), chromosomal disorders (odds ratio: 4.5000; CI 95%: 0.8022-25.2421; p=0.08), maternal infections (odds ratio: 1.4588; CI 95%: 0.2944-7.2299; p=0.6), Apgar score (odds ratio: 0.8951; CI 95%: 0.1069-7.4959; p=0.9), mechanical ventilation (odds ratio: 2.9867; CI 95%: 0.8986-9.9264; p=0.07), cerebral

Table 4. Maternal infections during pregnancy in children with Sensorineural Hearing Loss (SNHL) and with normal hearing.

| Maternal Infection | SNHL (N=12) | Normal Hearing(N=141) |
|--------------------|-------------|-----------------------|
| Citomegalovirus | 8.30% | 4.90% |
| Toxoplasmosis | 8.30% | 2.10% |
| Rubella | 8.30% | 0% |
| Escherichia Coli | 8.30% | 0.70% |
| Candida | 8.30% | 1.40% |
| Chlamydia | 0% | 1.40% |
| Syphilis | 0% | 0.70% |
| Mycoplasma | 0% | 1.40% |
| Hepatitis C | 0% | 0.70% |

complication (odds ratio: 0.5195; CI 95%:0.0637-4.2379; p=0.6), weight at the birth <1500 gr (odds ratio: 6.2796; CI 95%: 0.3601-109.5044; p=0.2), use of antibiotics (odds ratio:3.0114; CI 95%: 0.6353-14.2732; p=0.1), use of ototoxic antibiotics (odds ratio: 3.9241; CI 95%: 0.6955-15.6016; p=0.1), assisted procreation (odds ratio: 6.3182; CI 95%: 0.5303-752780; p=0.1), and consanguinity (odds ratio: 6.3196; CI 95%: 0.5398-752225; p=0.1) (Table 4).

DISCUSSION

SNHL in children is a condition that significantly affects speech, language and psychological development when in the bilateral severe and profound forms^{26,27}, and that may have social consequences and auditory symptoms such as tinnitus and hyperacusis when unilateral or in the mild and moderate forms²⁸⁻³². This study aimed to evaluate the prevalence of SNHL in newborns hospitalized in NICU, and the correlation of several risk factors with hearing loss. In our sample, the prevalence of SNHL observed in children hospitalized in NICU was 7.8%; nearly 60% of them had a profound hearing loss. The prevalence in our sample is significantly higher to that reported by Coenraad et al. (1.7%)²⁰, Hille et al. (3.1%)³³ and Robertson et al (3.2%)²⁴ this may be due to the small size of our sample. The majority of infants with SNHL in our population had a profound hearing loss; this is in accordance with Coenraad²⁰ and Robertson²⁴. Most of the children included in our study presented prematurity, a common reason of admission to NICU; this was equally present in children with SNHL and in normal hearing population but children with hearing loss had a slightly lower mean gestational age (28 weeks) compared to normal hearing children (31-32 weeks). Caesarian childbirth, twin pregnancy, sepsis and surgery were more common in children with a diagnosis of SNHL compared to normal hearing children; this data could be explained by the systemic hypoperfusion that may have an impact on the ear perfusion and contribute to inner cells death³⁴; furthermore, sepsis and surgery may increase the circulating reactive oxygen species (ROS) responsible of oxidative damage in the inner ear³²⁻³⁶. In case of maternal diseases, even if treated correctly with therapy, the risk of developing SNHL in our sample was slightly increased; this may follow the alteration of

the normal maternal homeostasis/metabolism that may determine both pressure variations and increasing of ROS able to damage the inner ear structure of children³⁷. We did not observe an increased prevalence of SNHL in babies hospitalized in NICU over five days, that underwent to antibiotics treatment and that presented a low weight at birth. These findings are in contrast with other authors' results and the JCIH, that observed with an increased risk of developing SNHL in these children¹⁴⁻³⁸. We attribute this finding to the small size of our sample. Similarly, it was not observed a higher prevalence of hearing loss in children with low Apgar score, maternal infections, mechanical ventilation, cerebral complication, assisted procreation and chromosomic disorders. This may be correlated with the characteristic of our sample and with the management of newborns in our NICU. The control of the infections by specific treatment administered since the early stage of pregnancy decreased the risk of viral infections; while the mechanic ventilation with personal assistance (several control daily) avoided quick changes of oxygenation values that might impact on the inner ear structures^{39,40}.

CONCLUSION

SNHL in newborns is correlated with hospitalization in NICU. The early diagnosis and intervention in children with hearing loss at <6 months of age leads to significantly better outcomes for speech and language development compared to non-treated children. Although universal newborn hearing screening programs allow early identification of children with hearing loss, a specific attention should be dedicated to children hospitalized in NICU, in which an accurate early audiological evaluation associated to a rigorous clinical medical collection of data is always necessary due to the higher risk of SNHL.

ACKNOWLEDGMENT

We acknowledge the support given by operators of Audiology and NICU Department of our University hospital.

CONFLICT OF INTEREST

The Author declares no conflict of interest

REFERENCES

1. Vohr B. Infants and children with hearing loss part 2: Overview. *Ment Retard Dev Disabil Res Rev.* 2003;9(4):218-9.
2. Vohr B. Overview: Infants and children with hearing loss-part I. *Ment Retard Dev Disabil Res Rev.* 2003;9(2):62-4.
3. Ralli M, Rolesi R, Anzivino R, Turchetta R, Fetoni AR. Acquired sensorineural hearing loss in children: current research and therapeutic perspectives. *Acta Otorhinolaryngol Ital.* 2017;37(6):500-8.
4. Mehl AL, Thomson V. Newborn hearing screening: the great omission. *Pediatrics.* 1998;101(1):E4.
5. Dedhia K, Graham E, Park A. Hearing Loss and Failed Newborn Hearing Screen. *Clin Perinatol.* 2018;45(4):629-43.
6. Kanji A, Khoza-Shangase K, Moroe N. Newborn hearing screening

- protocols and their outcomes: A systematic review. *Int J Pediatr Otorhinolaryngol.* 2018;115:104-9.
7. El-Hattab AW, Almannai M, Sutton VR. Newborn Screening: History, Current Status, and Future Directions. *Pediatr Clin North Am.* 2018;65(2):389-405.
 8. Ravi R, Gunjawate DR, Yerraguntla K, Rajashekhar B. Systematic review of knowledge of, attitudes towards, and practices for newborn hearing screening among healthcare professionals. *Int J Pediatr Otorhinolaryngol.* 2018;104:138-44.
 9. Turchetta R, Conti G, Marsella P, Orlando MP, Picciotti PM, Frezza S, Russo FY, Scorpecci A, Cammeresi MG, Giannantonio S, Greco A, Ralli M. Universal newborn hearing screening in the Lazio region, Italy. *Ital J Pediatr.* 2018;44(1):104.
 10. Cianfrone F, Mammarella F, Ralli M, Evetovic V, Pianura CM, Bellocchi G. Universal newborn hearing screening using A-TEOAE and A-ABR: The experience of a large public hospital. *J Neonatal Perinatal Med.* 2018;11(1):87-92.
 11. Uus K, Bamford J, Taylor R. An analysis of the costs of implementing the National Newborn Hearing Screening Programme in England. *J Med Screen.* 2006;13(1):14-9.
 12. Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P. Newborn and infant hearing loss: detection and intervention. *American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998-1999.* *Pediatrics.* 1999;103(2):527-30.
 13. Berg AO, Allan JD, Frame PS, Homer CJ, Johnson MS, Klein JD, et al. Newborn hearing screening: recommendations and rationale. *Am J Nurs.* 2002;102(11):83-9.
 14. American Academy of Pediatrics JCoIH. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. *Pediatrics.* 2007;120(4):898-921.
 15. Keihanidost Z, Tabrizi A, Amini E, Sedaghat M, Ghahremani A, Shariat M, et al. Risk Factors for Hearing Loss and Its Prevalence in Neonates Older than 6 Months with History of Hospitalization in Intensive Care Unit. *Iran J Child Neurol.* 2018;12(4):153-61.
 16. George L, Patel JB, Park N, Manimtim WM. Implementation of Updated Hearing Screen Guidelines in a Level IV NICU-A Quality Improvement Project. *Am J Perinatol.* 2019;36(3):296-302.
 17. Qi B, En H, Huang L. The review of newborn hearing screening program in neonatal intensive care unit. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2015;29(23):2103-6.
 18. Coenraad S, Toll MS, Hoeve HL, Goedegebure A. Auditory brainstem response morphology and analysis in very preterm neonatal intensive care unit infants. *Laryngoscope.* 2011;121(10):2245-9.
 19. Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for auditory neuropathy spectrum disorder in NICU infants compared to normal-hearing NICU controls. *Laryngoscope.* 2011;121(4):852-5.
 20. Coenraad S, Goedegebure A, van Goudoever JB, Hoeve LJ. Risk factors for sensorineural hearing loss in NICU infants compared to normal hearing NICU controls. *Int J Pediatr Otorhinolaryngol.* 2010;74(9):999-1002.
 21. Brown G. NICU noise and the preterm infant. *Neonatal Netw.* 2009;28(3):165-73.
 22. Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. *Arch Dis Child Fetal Neonatal Ed.* 2008;93(6):F462-8.
 23. Molini E, Calzolaro L, Lapenna R, Ricci G. Universal newborn hearing screening in Umbria region, Italy. *Int J Pediatr Otorhinolaryngol.* 2016;82:92-7.
 24. Robertson CM, Howarth TM, Bork DL, Dinu IA. Permanent bilateral sensory and neural hearing loss of children after neonatal intensive care because of extreme prematurity: a thirty-year study. *Pediatrics.* 2009;123(5):e797-807.
 25. Della Volpe A, Dipietro L, Ricci G, Pastore V, Paccone M, Pirozzi C, et al. Pre-treatment with Melamil Tripto((R)) induces sleep in children undergoing Auditory Brain Response (ABR) testing. *Int J Pediatr Otorhinolaryngol.* 2018;115:171-4.
 26. Rashid SMU, Mukherjee D, Ahmmed AU. Auditory processing and neuropsychological profiles of children with functional hearing loss. *Int J Pediatr Otorhinolaryngol.* 2018;114:51-60.
 27. Di Stadio A, Dipietro L, Toffano R, Burgio F, De Lucia A, Ippolito V, et al. Working Memory Function in Children with Single Side Deafness Using a Bone-Anchored Hearing Implant: A Case-Control Study. *Audiol Neurootol.* 2018;23(4):238-44.
 28. Nemholt S, Schmidt JH. Tinnitus and hyperacusis in Danish children and adolescents. *Ugeskr Laeger.* 2018;180(43).
 29. Ralli M, Greco A, Altissimi G, Tagliaferri N, Carchiolo L, Turchetta R, et al. Hyperacusis in Children: A Preliminary Study on the Effects of Hypersensitivity to Sound on Speech and Language. *Int Tinnitus J.* 2018;22(1):10-8.
 30. Myne S, Kennedy V. Hyperacusis in children: A clinical profile. *Int J Pediatr Otorhinolaryngol.* 2018;107:80-5.
 31. Ralli M, Balla MP, Greco A, Altissimi G, Ricci P, Turchetta R, et al. Work-Related Noise Exposure in a Cohort of Patients with Chronic Tinnitus: Analysis of Demographic and Audiological Characteristics. *Int J Environ Res Public Health.* 2017;14(9).
 32. Di Stadio A, Dipietro L, Ricci G, Della Volpe A, Minni A, Greco A, de Vincentiis M, et al. Hearing Loss, Tinnitus, Hyperacusis, and Diplacusis in Professional Musicians: A Systematic Review. *Int J Environ Res Public Health.* 2018;15(10).
 33. Hille ET, van Straaten HI, Verkerk PH, Dutch NNHSWG. Prevalence and independent risk factors for hearing loss in NICU infants. *Acta Paediatr.* 2007;96(8):1155-8.
 34. Kim SY, Choi BY, Jung EY, Park H, Yoo HN, Park KH. Risk factors for failure in the newborn hearing screen test in very preterm twins. *Pediatr Neonatol.* 2018;59(6):586-94.
 35. Fischer N, Mathonia NM, Hoellerich G, Vesper J, Pinggera L, Dejaco D, et al. Surviving murine experimental sepsis affects the function and morphology of the inner ear. *Biol Open.* 2017;6(6):732-40.
 36. Sergi B, Fetoni AR, Paludetti G, Ferraresi A, Navarra P, Mordente A, et al. Protective properties of idebenone in noise-induced hearing loss in the guinea pig. *Neuroreport.* 2006;17(9):857-61.
 37. Gul F, Muderris T, Yalciner G, Sevil E, Bercin S, Ergin M, et al. A comprehensive study of oxidative stress in sudden hearing loss. *Eur Arch Otorhinolaryngol.* 2017;274(3):1301-8.
 38. Suzuki N, Suzumura H. Relation between predischarge auditory brainstem responses and clinical factors in high-risk infants. *Pediatr Int.* 2004;46(3):255-63.
 39. Downs MP, Yoshinaga-Itano C. The efficacy of early identification and intervention for children with hearing impairment. *Pediatr Clin North Am.* 1999;46(1):79-87.
 40. Downs MP. Universal newborn hearing screening--the Colorado story. *Int J Pediatr Otorhinolaryngol.* 1995;32(3):257-9.